Navigation Links
Cyberonics Announces Investment in ImThera Medical
Date:10/5/2011

HOUSTON, Oct. 5, 2011 /PRNewswire/ -- Cyberonics, Inc. (NASDAQ: CYBX), a global leader in medical devices for the treatment and management of epilepsy, today announced an initial investment of $4 million in ImThera Medical, Inc. ("ImThera").  Based in San Diego, California, ImThera is an early-stage company developing a novel, implantable neurostimulation device for the treatment of obstructive sleep apnea ("OSA").

The investment in ImThera can total $12 million subject to the achievement of certain regulatory and clinical milestones.  Cyberonics is a minority shareholder with certain rights, including representation on ImThera's board of directors.  In addition, ImThera will raise up to $4 million from its private investors, for a total Series C placement of up to $16 million.

OSA is a serious, potentially life-threatening condition associated with significant long-term health problems and accompanying costs.  ImThera's Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy combines a multi-contact electrode specifically designed to control certain muscles of the tongue with an implantable pulse generator and an external programmer.  The company is currently pursuing CE Mark regulatory approval in the European Union and expects to initiate a pivotal clinical trial in the U.S. in the near future.

"OSA affects millions of people in the U.S. and around the world," said Dan Moore, Cyberonics' President and Chief Executive Officer.  "We are excited about the opportunity to invest in a promising new therapeutic neurostimulation technology outside our core business."

"ImThera is pleased to have Cyberonics as an investor and partner.  Cyberonics brings outstanding experience to our board, providing significant expertise to ImThera as we continue to execute our plan," stated Marcelo Lima, ImThera's Chairman, President and Chief Executive Officer.

About Cyberonics, Inc. and the VNS Therapy® System

Cyberonics, Inc. is a medical technology company with core expertise in neuromodulation.  The company developed and markets the VNS Therapy System, which is FDA-approved for the treatment of refractory epilepsy and treatment-resistant depression.  The VNS Therapy System uses an implanted medical device that delivers electrical pulsed signals to the vagus nerve.  Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberonics and the VNS Therapy System is available at www.cyberonics.com.

About ImThera

ImThera Medical is an early-stage company that has developed a novel, neurostimulation medical device for the treatment of Obstructive Sleep Apnea (OSA).  Through targeted tongue-muscle stimulation, ImThera's open-loop hypoglossal nerve multi-contact device delivers muscle tone to key tongue muscles during sleep, opening the upper airway and substantially reducing or eliminating OSA events.

ImThera's mission is to help patients live longer and enjoy better lives while substantially reducing health care costs related to serious complications associated with Obstructive Sleep Apnea. Additional information on ImThera and the THN Sleep System is available at www.imtheramedical.com.

Safe harbor statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements can be identified by the use of forward-looking terminology, including "may," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or other similar words.  Statements contained in this press release are based on information presently available to us and assumptions that we believe to be reasonable.  We are not assuming any duty to update this information if those facts change or if we no longer believe the assumptions to be reasonable. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning investing up to $12 million in ImThera while ImThera receives up to $4 million from other investors, developing ImThera's implantable neurostimulation device as a therapy for OSA and obtaining CE Mark approval, initiating and completing a pivotal clinical study in the U.S., and obtaining U.S. marketing approval for ImThera's implantable neurostimulation device.  Our actual results may differ materially.  Important factors that may cause actual results to differ include, but are not limited to: continued market acceptance of VNS Therapy™ and sales of our product; the development and satisfactory completion of clinical trials and/or market test and/or regulatory approval of VNS Therapy for the treatment of other indications; satisfactory completion of post-market studies required by the U.S. Food and Drug Administration as a condition of approval for the treatment-resistant depression indication; adverse changes in coverage or reimbursement amounts by third-parties; intellectual property protection and potential infringement claims; maintaining compliance with government regulations and obtaining necessary government approvals for new indications; product liability claims and potential litigation; reliance on single suppliers and manufacturers for certain components; the accuracy of management's estimates of future expenses and sales; the results of the previously disclosed governmental inquiries; the potential identification of material weaknesses in our internal controls over financial reporting; risks and costs associated with such governmental inquiries and any litigation relating thereto or to our stock option grants, procedures, and practices and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC).  For a detailed discussion of these and other cautionary statements, please refer to our most recent filings with the SEC, including our Annual Report on Form 10-K for the fiscal year ended April 29, 2011.

Contact Information
Greg Browne, CFO
Cyberonics, Inc.
100 Cyberonics Blvd.
Houston, TX 77058
Phone:  (281) 228-7262
Fax:  (281) 218-9332
ir@cyberonics.com

Fran Bosecker, Account Director
Vantage Communications for ImThera Medical
Phone: (845) 536-1416
fbosecker@pr-vantage.com


'/>"/>
SOURCE Cyberonics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics to Participate in 2011 UBS Global Life Sciences Conference
2. Cyberonics Reports Fiscal 2012 First Quarter Results
3. Cyberonics to Report Fiscal Year 2012 First Quarter Results and Host Conference Call on August 25, 2011
4. Cyberonics Reports Record Fiscal 2011 Results and Provides Fiscal 2012 Guidance
5. Cyberonics to Participate in 2011 Jefferies Global Healthcare Conference
6. Cyberonics Reports Strong Fiscal 2011 Third Quarter Results and Increases Guidance
7. Cyberonics to Report Fiscal Year 2011 Third Quarter Results and Host Conference Call on March 2, 2011
8. Cyberonics to Present at 22nd Annual Piper Jaffray Health Care Conference
9. Cyberonics Announces Conference Call to Discuss Fiscal Year 2011 Second Quarter Financial Results
10. Cyberonics Reports Inducement Equity Awards Under NASDAQ Listing Rule 5635(c)(4)
11. Cyberonics to Participate in Upcoming September Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... , Oct. 12, 2017 West ... in innovative solutions for injectable drug administration, today announced ... the market opens on Thursday, October 26, 2017, and ... results and business expectations at 9:00 a.m. Eastern Time. ... or 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Hill-Rom Holdings, Inc. ... Aspen Surgical facility in Las Piedras, Puerto ... scalpels and blades. ... that the facility sustained minor structural damage, temporary loss ... Maria. Repairs have been completed, manufacturing operations have resumed, ...
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health & ... by Moonlight to raise money for the American Heart Association Heart Walk. Teams of ... will work together to keep their treadmills moving for 5 hours. Treadmills will start ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health Literacy Innovations (HLI), ... software tool, and the Cancer Patient Education Network (CPEN), an independent professional organization ... a new strategic alliance. , As CPEN’s strategic partner, HLI will help ...
Breaking Medicine News(10 mins):